Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afamelanotide in Acute Arterial Ischaemic Stroke
NCT04962503Phase 2Completed
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- Feb 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Afamelanotide in arterial ischemic stroke (AIS), sponsored by Clinuvel Pharmaceuticals. Started Jun 2021; status: completed.
02
Drugs
Afamelanotide
03
Conditions
arterial ischemic stroke (AIS)
Beyond the preview
Go deeper on NCT04962503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04962503.